HFA 24: Timing of Cardio-Kidney Protection with SGLT2i

Published: 13 May 2024

  • Views:

    Views Icon 71
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

HFA 24 - We are joined by Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, US) to discuss the findings from a study of four large-scale placebo controlled-trials investigating the timing of cardio-kidney protection with SGLT2 inhibitors.

4 trials that sampled distinct patient populations were enrolled in the trial - the CANVAS program, the CREDENCE trial, DAPA-HF and DELIVER. Across each randomized trial, investigators assessed the relative timing of effects on multiple cardiovascular and kidney endpoints.

Findings showed that heart failure events were strikingly modifiable, and appeared very early. This finding was sustained not just in patients with existing heart failure, but also in populations of patients with kidney disease and type II diabetes. Kidney disease protection took some time to demonstrate between-arm differences in protection. Mortality endpoints were also similar in terms of clinical benefits. In contrast, effects on MACE and heart failure occurred rapidly. 

Interview Questions:

  1. What is the background of this study?
  2. What is the study design and patient population?
  3. What were the findings presented at HFA 24?
  4. Have you come across any results that were surprising or unexpected?
  5. What are the take-home messages for practice?
  6. Where are the knowledge gaps, and what are the next steps?

Recorded onsite at HFA 2024, Lisbon.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editor: Jordan Rance, Mirjam Boros
Video Specialist: Dan Brent
Interviewer: Jonathan McKenna


You must be to comment. If you are not registered, you can register here.
Mohammed Elmobarak